Tailored Life Sciences Insurance

In 2023, Berkley Life Sciences published a blog post titled PFAS “Forever Chemicals” in Medical and Life Sciences Products – Who Should Be Worried?. At that time, most per- and polyfluoroalkyl substances (PFAS) litigation to date focused on lawsuits against PFAS manufacturers, alleging personal injury from PFAS exposure. Since then, PFAS litigation has evolved, and both the U.S. Food and Drug Administration (FDA) and European Chemicals Agency (ECHA) have issued updates, warranting a fresh look at this topic.

Montana's Right to Try laws - Senate Bill 422 (2023) and Senate Bill 535 (2025) allow any patient, not just those with terminal illness, to access experimental treatments that have passed Phase 1 safety trials. Clinics offering these treatments must be licensed and contribute to patient support funds. Patients must provide informed consent before treatment.

Traditional pediatric prosthetics present significant challenges for families and clinicians alike. These devices are often expensive, difficult to customize, and inaccessible to children in remote or low-income areas. Because children grow quickly, prosthetics require frequent replacements and adjustments, adding financial and logistical strain.